As stated above, numerous tumors are associated with SETD2 genetic alterations, including clear-cell renal carcinomas which show the highest mutation frequency among SETD2-related cancers, but also leukemias and lymphomas, non-small-cell lung tumors, gastric tumors and gliomas. This evidence concerns the gene SETD2 and clear cell renal carcinoma.